Skip to main content
Maged Ghaly, MD, Radiation Oncology, Smithtown, NY

MagedMofiedGhalyMD

Radiation Oncology Smithtown, NY

Central Nervous System Cancer, Gastrointestinal Cancer, Head & Neck

Assistant Professor, Radiation Medicine, Hofstra North Shore-LIJ

Dr. Ghaly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ghaly's full profile

Already have an account?

  • Office

    989 W Jericho Tpke
    Smithtown, NY 11787
    Phone+1 631-864-5600
    Fax+1 631-864-5612

Education & Training

  • New York-Presbyterian Brooklyn Methodist Hospital
    New York-Presbyterian Brooklyn Methodist HospitalResidency, Radiation Oncology, 1998 - 2002
  • New York-Presbyterian Brooklyn Methodist Hospital
    New York-Presbyterian Brooklyn Methodist HospitalInternship, Internal Medicine, 1997 - 1998
  • Cairo University School of Medicine
    Cairo University School of MedicineClass of 1992

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2002 - 2025
  • PA State Medical License
    PA State Medical License 2001 - 2001
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Top Doctors: New York Metro Area Castle Connolly, 2014
  • Newsday - Top Doctors on Long Island Castle Connolly, 2012-2014

Publications & Presentations

PubMed

Press Mentions

  • Medical Grade Cement May Help Cancer Patients Whose Disease Has Spread to the Spine
    Medical Grade Cement May Help Cancer Patients Whose Disease Has Spread to the SpineApril 18th, 2017
  • Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in Its Core Focus Area of Cancer Supportive Care
    Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in Its Core Focus Area of Cancer Supportive CareApril 19th, 2024
  • Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
    Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis ProductMay 28th, 2024